[Treatment of urosepsis]

Orv Hetil. 2008 Jun 8;149(23):1095-9. doi: 10.1556/OH.2008.28373.
[Article in Hungarian]
No abstract available

Publication types

  • Review

MeSH terms

  • Anti-Infective Agents / therapeutic use*
  • Blood Glucose / metabolism
  • Humans
  • Protein C / therapeutic use
  • Pyelonephritis / complications
  • Pyelonephritis / therapy
  • Recombinant Proteins / therapeutic use
  • Renal Insufficiency / etiology
  • Renal Insufficiency / prevention & control
  • Respiratory Insufficiency / etiology
  • Respiratory Insufficiency / prevention & control
  • Risk Factors
  • Sepsis / therapy
  • Urinary Catheterization / adverse effects
  • Urinary Tract Infections / complications
  • Urinary Tract Infections / diagnosis
  • Urinary Tract Infections / drug therapy
  • Urinary Tract Infections / etiology
  • Urinary Tract Infections / prevention & control
  • Urinary Tract Infections / therapy*
  • Venous Thrombosis / etiology
  • Venous Thrombosis / prevention & control

Substances

  • Anti-Infective Agents
  • Blood Glucose
  • Protein C
  • Recombinant Proteins
  • drotrecogin alfa activated